June 26, 2017: Markets opened higher Monday but the Nasdaq Composite turned south early on and remained there for most of the day. The tech sector was the day’s poorest performer while utilities and telecom performed best. WTI crude oil for August delivery settled at $43.38 a barrel, up 0.9% on the day. August gold dropped 0.8% for the day to settle at $1,246.40. Equities were headed for a mixed close shortly before the bell as the DJIA traded up 0.17% for the day, the S&P 500 traded up 0.11%, and the Nasdaq Composite traded down 0.22%.
The DJIA stock posting the largest daily....More>>>
According to Goldman Sachs, hedge fund managers aren’t buying tech giant Apple Inc. (NYSE: AAPL).
Pundits are abuzz with theories. Maybe it’s because Apple has been forced to move iCloud data to Chinese data centers. Maybe these hedge fund managers know something the rest of us don’t. Or maybe they just think it’s overvalued.
Money Morning Chief Investment Strategist Keith Fitz-Gerald appeared on FOX Business Network’s “Varney & Co.” today to set the record straight. He was a Wall Street insider for decades before he started sharing....More>>>
President Donald Trump is jockeying to end the Iran nuclear deal once and for all, and Iran wants to make us pay.
Add this to North Korea’s constant threats, naval clashes in the South China Sea, and the recent Saudi Purge, and it can be tempting to stuff your money in your mattress or invest in commodities like gold and silver.
But there’s a better way to weather these mounting global tensions – an investing strategy that works no matter what ugliness is happening around the world.
Which is good news, because Iran is none too happy that President....More>>>
Related ZIOP Mid-Afternoon Market Update: Marvell Gains On Earnings Beat; Hibbett Shares Plummet ZIOPHARM Announces Clinical Data On Brain Cancer Drug
Related FLDM 20 Stocks Which Rallied Three Days On Increasing Volume Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop Fluidigm proposes poison pill against potential hostile takeover; shares slump 7% (Seeking Alpha)
Aurinia (NASDAQ:AUPH) is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerularsclerosis and minimal change disease (MCD). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topic formulation, for the treatment of dry eye syndrome (NYSEARCA:DES). (here)
Aurinia Pharmaceuticals (AUPH) may very well be quite the investment opportunity. Its only....More>>>